Brigham Does Not Contest Plaintiffs’ Offers of Proof as Morcellation Cases Proceed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This article is part of The Cancer Letter's How Medical Devices Do Harm series.

BRIGHAM & WOMEN’S HOSPITAL chose not to contest the plaintiffs’ offers of proof in two medical malpractice lawsuits against the Boston hospital at a Massachusetts tribunal May 13.

The two lawsuits related to power morcellation will now be allowed to proceed. The suits were filed by Richard Kaitz and Hooman Noorchashm, whose wives, Erica Kaitz and Amy Reed, had the controversial minimally invasive surgery at Brigham in 2012 and 2013, respectively.

The procedure, which until recently was performed in an estimated 100,000 women annually in the U.S., is the focal point of a two-year debate that has divided the surgical field. When a previously undiagnosed malignant tumor—usually a sarcoma—is present, the procedure spreads the cancerous tissue, upstaging the disease (The Cancer Letter, How Medical Devices Do Harm).

Erica died Dec. 7, 2013 from metastatic leiomyosarcoma, and Reed, formerly an anesthesiologist at Beth Israel Deaconess Medical Center, is undergoing treatment for stage IV disease.

“It’s a rare case that the defendant does not contest the plaintiff’s offer of proof at the tribunal stage,” said Tom Greene, the attorney representing Kaitz and Noorchashm’s families. Brigham did not respond to an email from The Cancer Letter by deadline.

Massachusetts law requires that a tribunal—consisting of a judge, an attorney, and a physician—review medical malpractice cases to screen out lawsuits that are not supported by clinical evidence or fact. The process determines whether there is sufficient evidence for the case to proceed.

According to the Massachusetts Medical Society, tribunals screen out approximately 16 percent of all medical malpractice cases in the state.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login